AFL vs GL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: GL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AFL and GL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AFL and GL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aflac Incorporated, headquartered in Columbus, Georgia, is the largest provider of supplemental health insurance sold at the worksite in the United States and the leading writer of cancer and medical insurance in Japan. The products are narrow by design: cash-benefit policies that pay the policyholder directly when a covered event happens (a cancer diagnosis, a hospital stay, an accident), sitting alongside rather than replacing major medical coverage. Aflac Japan, distributed through banks, independent agencies and the Japan Post network, is the larger of the two segments and produced pretax adjusted earnings of ~$759 million in Q1 2026 against ~$363 million for Aflac US. Because premiums are small, recurring and paid by payroll deduction or bank draft, the revenue base is unusually stable compared with property, casualty or annuity writers.

Full AFL guide

Globe Life Inc. is a Texas-based insurance holding company (formerly Torchmark) that underwrites individual life insurance and supplemental health insurance aimed at lower-to-middle-income American families. It sells through captive and exclusive agency channels under subsidiaries including American Income Life, Liberty National, Family Heritage, United American, and the direct-to-consumer Globe Life brand, and reports across life, health, and investment segments. The model emphasizes a large in-force book of small-face-amount policies with high persistency, which produces recurring premium and a sizable investment portfolio.

Full GL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AFL drivers: Japan third-sector product refresh; Buyback-driven earnings per share.
• GL drivers: Premium growth across agency divisions; High return on equity and book-value compounding.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. For GL, reputational and legal exposure is the defining risk: the 2024 Fuzzy Panda short report alleged systemic insurance fraud (policies for deceased or fictitious people, forged signatures, unauthorized withdrawals) concentrated in agents at American Income Life, and shareholder and derivative lawsuits alleging the company misled investors remain ongoing even after the DOJ probe closed without action.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AFL if you believe its drivers more; GL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AFL and GL guides.

AFL. Aflac's reported revenue line is noisier than the underlying business because it absorbs net investment gains and losses and yen translation, which is why 2025 revenue fell while adjusted earnings per share rose. The market has generally valued the stock in the low-to-mid teens on earnings, a discount to the broad market that reflects the shrinking Japanese premium base and the currency exposure, offset by high margins and heavy buybacks. Q2 2026 results were scheduled for release after the close on August 6, 2026, with consensus near ~$1.77 in adjusted EPS on ~$4.19 billion of revenue.

GL. GL trades at a low-teens trailing price-to-earnings multiple, well below the broad market, reflecting both its steady insurance-underwriting profile and the reputational discount lingering from the 2024 allegations. Return on equity in the high teens and book value per share near $77 support a valuation that leans on consistent earnings and buybacks rather than high growth. Figures are approximate and drawn from 2025 results and 2026 quarterly reporting.

Headline figures (approximate, August 2026): AFL shows revenue (ttm) ~$18.2 billion (FY2025 was ~$17.2 billion, down ~9.3% year over year), net earnings (ttm) ~$4.6 billion; Q1 2026 net earnings were ~$1.0 billion, or ~$1.98 per diluted share, adjusted eps ~$7.49 for FY2025; Q1 2026 adjusted EPS was ~$1.75, up ~5.4% year over year, market cap / p/e (ttm) ~$63 billion at a share price near ~$124, or roughly ~14x trailing earnings of ~$8.75 per share; GL shows revenue (ttm) ~$6.0B, market cap ~$13.9B, diluted eps (2025) ~$14.07, 2026 eps guidance ~$15.40 to $15.90.

AFL and GL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AFL and GL exposure against your real portfolio. It is not an investment adviser.